Search clinical trials for: Obinutuzumab administration

Total 3535 results

Vivatech

Completed

Investigation of Kritech Efficacy on Subjects Having Functional Discomfort Associated to Joints and Muscles Disorders (Easykrill)

Pain

France
VA Loma Linda Health Care System
Actelion

Completed

Effect of Bosentan on Exercise Capacity at High Altitude

Pulmonary Hypertension | Altitude

United States
Cairo University

Recruiting

Oropharyngeal Administration Of Colostrum For Preventing Necrotizing Enterocolitis in Preterrms

Prematurity

Egypt
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Treatment

China
University Medical Center Groningen
Erasmus Medical Center

Completed

Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging (TARGET)

Papillary Thyroid Cancer | Lymph Node Metastases

Netherlands
Qianfoshan Hospital

Not yet recruiting

Obinutuzumab in the Management of Idiopathic Membranous Nephropathy

Idiopathic Membranous Nephropathy
Michael Choi
Pharmacyclics LLC.

Withdrawn

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Chronic Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia (2023CD20ITP)

Immune Thrombocytopenia | Treatment

China
Hoffmann-La Roche

Completed

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

Follicular Lymphoma | Chronic Lymphocytic Leukemia

Korea, Republic of
French Innovative Leukemia Organisation
Hoffmann-La Roche

Recruiting

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (GLORIFY)

Richter Syndrome

France
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (FIL_GAZEBO)

Follicular Lymphoma

Italy
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China

Obinutuzumab | Rapid Infusion | Intravenous Infusion Reaction

China
Paolo Ghia

Recruiting

Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL (FIGHT)

Chronic Lymphocytic Leukemia

Italy
Polish Myeloma Consortium
Roche Pharma AG; Bioscience, S.A.

Unknown

A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 (OBI-1)

Waldenstrom Macroglobulinemia

Poland
University of Ulm
AbbVie; Roche Pharma AG; Janssen-Cilag Ltd.; German CLL Study Group

Completed

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL (CLL2-GiVe)

Leukemia, Lymphocytic, Chronic

Germany
TG Therapeutics, Inc.

Completed

TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Bnai Zion Medical Center
Tel-Aviv Sourasky Medical Center

Recruiting

A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome;

Richter's Syndrome

Israel
BiondVax Pharmaceuticals ltd.

Completed

A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

Healthy | Influenza

Israel
Heidelberg University
Roche Pharma AG

Active, not recruiting

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (GAZAI)

Stage II Grade 1 Follicular Lymphoma | Stage II Grade 2 Follicular Lymphoma | Stage I Follicular Lymphoma Grade 1 | Stage II Follicular Lymphoma Grade 2

Germany
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic Lymphoma Group

Active, not recruiting

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

CLL

Netherlands, Denmark
Aura Biosciences

Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
Dalian Medical University

Not yet recruiting

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Mantle Cell Lymphoma

China
Incyte Corporation

Withdrawn

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Marginal Zone Lymphoma (MZL) | Follicular Lymphoma ( FL)
Nantes University Hospital
Roche Pharma AG; Janssen, LP

Active, not recruiting

A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients (OAsIs)

Mantle Cell Lymphoma

France, United Kingdom
Mayo Clinic
Genentech, Inc.

Active, not recruiting

Obinutuzumab in Primary FSGS

Primary Focal Segmental Glomerulosclerosis

United States
Deok-Hwan Yang
Roche Pharma AG

Unknown

A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Chronic Lymphocytic Leukemia

Korea, Republic of
Assistance Publique - Hôpitaux de Paris
Roche Pharma AG

Recruiting

Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF (OBILUP)

Lupus Nephritis | Systemic Lupus Erythematosus (SLE)

France
Abramson Cancer Center at Penn Medicine
Genentech, Inc.

Recruiting

CAR-T Followed by Bispecific Antibodies

DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma

United States
Menarini Group

Terminated

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults (FLORET)

Tumor Lysis Syndrome

Spain, Hungary, Italy, Bulgaria
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
Hoffmann-La Roche

Completed

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Spain
Assistance Publique - Hôpitaux de Paris

Recruiting

Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome (OBIRINS)

Steroid-Dependent Nephrotic Syndrome | Steroid-Sensitive Nephrotic Syndrome

France
Hospital de Clinicas de Porto Alegre
Federal University of Rio Grande do Sul

Unknown

Evaluation of Evening Versus Morning Levothyroxine Intake in Elderly (MONIALE)

Aging | Interaction Drug Food | Primary Hypothyroidism

Brazil
Affiliated Hospital of Nantong University

Not yet recruiting

Obinutuzumab in Chinese Real-world Patients With iNHL

Lymphomas Non-Hodgkin's B-Cell

China
Hoffmann-La Roche

Completed

Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) (URBAN)

Follicular Lymphoma

Italy
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

B Cell Lymphoma

China
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Focus Group in Collecting Feedbacks From Indoor Tanning Bed Users for Social Media-Delivered Intervention Development

Health Status Unknown

United States
University of Cologne

Recruiting

Regulation of Extracellular Sodium in End Stage Renal Disease Upon Volume and Electrolyte Challenges (RESERVE)

Hyponatremia

Germany
Camilo Jose Cela University

Completed

Effects of Oral Salt Supplementation on Physical Performance During a Half-ironman (SALTED)

Hyponatremia

Spain
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Non-alcoholic Steatohepatitis

Korea, Republic of
Munich Municipal Hospital
German CLL Study Group

Unknown

CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

Chronic Lymphocytic Leucemia

Germany
Academisch Medisch Centrum - Universiteit van Amsterdam...

Recruiting

Timecost of Intranasal Versus Intravenous Analgesia in Traumatic Pain

Analgesia | Acute Pain Due to Trauma

Netherlands
Centre Oscar Lambret
Centre Hospitalier Universitaire de Besancon

Terminated

Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302) (PRAMECE-1302)

Neoplasm Metastases

France
Mayo Clinic

Recruiting

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Fibrillary Glomerulonephritis

United States
Christian Buske
Roche Pharma AG; University of Ulm; Zentrum für Klinische Studien Ulm; X-act Cologne... and other collaborators

Active, not recruiting

Obinutuzumab in Marginal Zone Lymphoma

Marginal Zone Lymphoma

Germany
Case Comprehensive Cancer Center
Genentech, Inc.

Withdrawn

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

Post-transplant Lymphoproliferative Disorder | PTLD
Peking Union Medical College Hospital

Recruiting

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Marginal Zone Lymphoma

China
Johannes Gutenberg University Mainz
Roche Pharma AG; Servier

Completed

GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

Lymphoma, Non-Hodgkin

Germany
University of California, San Diego
Pharmacyclics LLC.

Active, not recruiting

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Chronic Lymphocytic Leukemia

United States
Genentech, Inc.

Completed

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Lymphocytic Leukemia, Chronic

United States

3

Subscribe